

General information about company	
Scrip code*	543064
NSE Symbol*	COHANCE
MSEI Symbol*	NOTLISTED
ISIN*	INE03QK01018
Name of company	COHANCE LIFESCIENCES LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	28-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	27-03-2025
Description of presentation currency	INR
Level of rounding	Crores
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	CONTRACT DEVELOPMENT AND MANUFACTURING
Start date and time of board meeting	28-05-2025 15:25
End date and time of board meeting	28-05-2025 17:10
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-	NA

Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (IA)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	03-02-2025
Indicate Company website link for updated RPT policy of the Company	https://www.suvenpharm.com/pdf/Investors/corporategovernance/policies/Policy%20on%20materiality%20of%20RPT%20and%20dealing%20with%20RPT.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for	No Not Applicable

the Default on Loans and Debt Securities is applicable to the entity?	
--	--

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Unaudited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	330.17	1093.51
	Other income	6.63	53.98
	Total income	336.8	1147.49
2	Expenses		
(a)	Cost of materials consumed	66.98	212.51
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	63.65	86.53
(d)	Employee benefit expense	52.72	198.3
(e)	Finance costs	2.3	8
(f)	Depreciation, depletion and amortisation expense	15.19	57.2
(g)	Other Expenses		
1	Other Expenses	79.64	233.6
	Total other expenses	79.64	233.6
	Total expenses	280.48	796.14
3	Total profit before exceptional items and tax	56.32	351.35
4	Exceptional items	0	0
5	Total profit before tax	56.32	351.35
6	Tax expense		
7	Current tax	2.65	92.37
8	Deferred tax	9.33	-12.73
9	Total tax expenses	11.98	79.64
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	44.34	271.71
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	44.34	271.71
17	Other comprehensive income net of taxes	0.73	0.57
18	Total Comprehensive Income for the period	45.07	272.28
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	Details of equity share capital		
	Paid-up equity share capital	25.46	25.46
	Face value of equity share capital	1	1
22	Reserves excluding revaluation reserve		2290.09
23	Earnings per share		
1	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	1.74	10.67

	Diluted earnings (loss) per share from continuing operations	1.73	10.62	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	1.74	10.67	
	Diluted earnings (loss) per share from continuing and discontinued operations	1.73	10.62	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)		

Text Block	
Textual Information(4)	Since the characters in the notes exceed the set limit, it is requested to refer to the detailed notes in PDF result as uploaded on the Stock Exchanges.

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	623.44
	Capital work-in-progress	253.15
	Investment property	0
	Goodwill	60.25
	Other intangible assets	1.1
	Intangible assets under development	0.78
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets	
	Non-current investments	924.64
	Trade receivables, non-current	0
	Loans, non-current	4.55
	Other non-current financial assets	8.46
	Total non-current financial assets	937.65
	Deferred tax assets (net)	0
	Other non-current assets	2.68
	Total non-current assets	1879.05
2	Current assets	
	Inventories	154.12
	Current financial asset	
	Current investments	191.56
	Trade receivables, current	242.47
	Cash and cash equivalents	19.36
	Bank balance other than cash and cash equivalents	3.26
	Loans, current	0.39
	Other current financial assets	0.43
	Total current financial assets	457.47
	Current tax assets (net)	0
	Other current assets	97.17
	Total current assets	708.76
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	2587.81
	Total current assets	708.76
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	2587.81
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	25.46
	Other equity	2290.09
	Total equity attributable to owners of parent	2315.55
	Non controlling interest	
	Total equity	2315.55
2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	

	Borrowings, non-current	0
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	23.94
	Total non-current financial liabilities	23.94
	Provisions, non-current	0
	Deferred tax liabilities (net)	34.79
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	58.73
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	70
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	11.08
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	59.95
	Total Trade payable	71.03
	Other current financial liabilities	50.52
	Total current financial liabilities	191.55
	Other current liabilities	5.67
	Provisions, current	15.4
	Current tax liabilities (Net)	0.91
	Deferred government grants, Current	0
	Total current liabilities	213.53
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	272.26
	Total equity and liabilities	2587.81
	Disclosure of notes on assets and liabilities	Textual Information(1)

Other Comprehensive Income			
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Unaudited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	Items that will not be reclassified to Profit or Loss	0.97	0.76
	Total Amount of items that will not be reclassified to profit and loss	0.97	0.76
2	Income tax relating to items that will not be reclassified to profit or loss	0.24	0.19
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income	0.73	0.57

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	351.35
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	6.39
	Adjustments for decrease (increase) in inventories	77.07
	Adjustments for decrease (increase) in trade receivables, current	-146.89
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	0
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	58.66
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	0
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	57.2
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0.55
	Adjustments for dividend income	0
	Adjustments for interest income	0.77
	Adjustments for share-based payments	14.91
	Adjustments for fair value losses (gains)	4.08
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-41.14
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	30.06
	Net cash flows from (used in) operations	381.41
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	80.38
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	301.03
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	805.96
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0

	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	138.9
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	953.64
	Purchase of other long-term assets	330.35
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	0.62
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0.01
	Net cash flows from (used in) investing activities	-320.94
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	31.42
	Repayments of borrowings	0
	Payments of lease liabilities	7.29
	Dividends paid	0
	Interest paid	3.32
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	20.81
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	0.9
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	0.9
	Cash and cash equivalents cash flow statement at beginning of period	18.46
	Cash and cash equivalents cash flow statement at end of period	19.36

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)																							
													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1	Suven Pharmaceuticals Limited	██████	Cohance lifesciences limited	██████	Common Promoter	Sale of goods or services		Approved				0.14	0	0									
2	Suven Pharmaceuticals Limited	██████	Cohance lifesciences limited	██████	Common Promoter	Any other transaction	Jobwork Charges	Approved				0.18	0	0									
3	Suven Pharmaceuticals Limited	██████	Cohance lifesciences limited	██████	Common Promoter	Any other transaction	Consultancy Charges	Approved				0.08	0	0									
4	Suven Pharmaceuticals Limited	██████	Cohance lifesciences limited	██████	Common Promoter	Any other transaction	Sharing Income	Approved				0.7	0	0									
5	Suven Pharmaceuticals Limited	██████	Cohance lifesciences limited	██████	Common Promoter	Any other transaction	Rental expenses	Approved				0.05	0	0									
6	Suven Pharmaceuticals Limited	██████	Casper Pharma Private Limited	██████	Wholly Owned Subsidiary	Any other transaction	Rental expenses	Approved				0.01	0	0									
7	Suven Pharmaceuticals Limited	██████	Casper Pharma Private Limited	██████	Wholly Owned Subsidiary	Sale of goods or services		Approved				0.47	0	0									
8	Suven Pharmaceuticals Limited	██████	Sapala Organics Private Limited	██████	Subsidiary	Any other transaction	Consultancy Charges	Approved				0.14	0	0									
9	Casper Pharma Private Limited	██████	Suven Pharmaceuticals Limited	██████	Holding Company	Any other transaction	Rental expenses	Approved				0.01	0	0									
10	Casper Pharma Private Limited	██████	Suven Pharmaceuticals Limited	██████	Holding-Subsidiary	Purchase of goods or services		Approved				0.47	0	0									
11	Casper Pharma Private Limited	██████	Cohance lifesciences limited	██████	Common Promoter of Holding Company	Any other transaction	Rental expenses	Approved				0.03	0	0									
12	Sapala Organics Private Limited	██████	Sampada Laboratories Pvt Ltd	██████	Enterprise over which KMP have significant influence	Any other transaction	House Keeping & Security Services	Approved				0.31	0	0									
13	Sapala Organics Private Limited	██████	Sampada Laboratories Pvt Ltd	██████	Enterprise over which KMP have significant influence	Any other transaction	Travelling Expenses	Approved				0.02	0	0									
14	Sapala Organics Private Limited	██████	Sampada Laboratories Pvt Ltd	██████	Enterprise over which KMP have significant influence	Any other transaction	Reimbursement of Gratuity	Approved				0.01	0	0									
15	Sapala Organics Private Limited	██████	Sampada Laboratories Pvt Ltd	██████	Enterprise over which KMP have significant influence	Any other transaction	Reimbursement of car maintenance	Approved				0.04	0	0									
16	Sapala Organics Private Limited	██████	Rasayan Inc	██████	Shareholder	Sale of goods or services		Approved				0.14	0	0.14									
17	Sapala Organics Private Limited	██████	Rasayan Inc	██████	Shareholder	Any other transaction	International Travelling Expenses	Approved				0.03	0	0									
18	Sapala Organics Private Limited	██████	Rasayan Inc	██████	Shareholder	Any other transaction	Business Promotion Expenses	Approved				0.61	0	0									

[illegible]

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Walker Chandiok & CO LLP & Co	Yes	31-05-2025